LBA47 Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study
Explore this paper's citation graph
- Type
- article
- Published
- 2024-09-01
- Cited by
- 3
- References
- 0
- Access
- Open access
- OpenAlex
- https://openalex.org/W4402565581
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:272718217
Keywords
Nivolumab, Ipilimumab, Medicine, Metastatic melanoma, Melanoma
References
No references recorded for this paper.
Cited by
Related papers
- Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients
- Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma
- Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
- TNFSF9 is associated with favor tumor immune microenvironment in patients with renal cell carcinoma who are treated with the combination therapy of nivolumab and ipilimumab
- The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
- Japanese real‐world study of sequential nivolumab and ipilimumab treament in melanoma
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- Combined immunotherapy improves survival in metastatic melanoma
- Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma.